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The Link(er) to NF-kB Activation
Antigen receptor-induced NF-kB activation depends
on receptor-proximal and -distal signaling events.
Two papers in this issue of Immunity demonstrate that
PKC-dependent phosphorylation of CARMA1 is the
critical molecular link that controls the activation of
the IKK signalosome and NF-kB.
The adaptive immune response is initiated by the anti-
gen receptor-dependent activation of signaling path-
ways that control the rapid proliferation and differentia-
tion of lymphocytes to become effector cells. One of the
earliest events is the activation of tyrosine kinases,
which in turn regulate a restricted set of signaling com-
ponents that control inducible gene transcription.
Among these are the B cell-specific classical PKC family
member PKCb and its functional T cell homolog, the
novel PKC family member PKCq. Targeted deletion of
these molecules in mice leads to defects in B and T cell
activation, respectively, that correlate with impaired
activation of the transcription factor nuclear factor-kB
(NF-kB) (Sun et al., 2000; Pfeifhofer et al., 2003; Saijo
et al., 2002; Su et al., 2002). In quiescent cells, NF-kB
is retained in the cytoplasm by binding to its inhibitor,
IkB. Upon lymphocyte activation, this inhibition is re-
leased by activation of the IkB kinase complex, IKK,
which induces phosphorylation and subsequent degra-
dation of IkB.
A major issue in the field has been the identification of
the downstream targets of PKCb and PKCq that make
the link to the activation of the IKK complex. The pro-
teins CARMA1, BCL10, and MALT1/paracaspase have
been recently identified as signaling components that
act downstream of these PKC family members
(Figure 1A; Thome, 2004), but the molecular mechanism
involved has remained a mystery. CARMA1 is a caspase
recruitment domain (CARD)-containing member of the
membrane-associated guanylate kinase (MAGUK) fam-
ily that binds the adaptor protein BCL10 via its N-termi-
nal CARD. The N-terminal region of CARMA1 also con-
tains a coiled coil motif that contributes to MALT1
binding and that is separated from the MAGUK-typical
C-terminal domains by an extended linker region with
no obvious homology to other known domains.
Now, two studies in this issue of Immunity reveal an
important functional role of the CARMA1 linker and
show that phosphorylation of this region by PKCq (in
T cells) or PKCb (in B cells) relays antigen receptor-
induced PKC activation to the downstream signaling
events controlling IKK activation (Figure 1B; Matsumoto
et al., 2005; Sommer et al., 2005).
Matsumoto, Wang, and colleagues (2005) had ob-
served that BCL10 associated with a phospho-protein,
subsequently identified as CARMA1, upon T cell activa-
tion. Previous work from the same laboratory had re-
vealed that PKCq could bind to the CARMA1 linkerregion in vitro (Wang et al., 2004). Focusing on theoret-
ically predicted conserved PKC phosphorylation sites,
the authors identified Ser552 as the major PKCq target
in vitro, and additional Ser residues 555 and 645 as sites
relevant for NF-kB signaling. In vivo peptide mapping
experiments, on the other hand, identified Ser552 and
Ser565 (a site that does not match the PKC substrate
consensus) as sites that are phosphorylated upon
PMA/CD28 stimulation and that are required to func-
tionally reconstitute CARMA1-deficient cells.
The study of Sommer et al. (2005) addresses the same
issue in both B and T cell models. The observation that
PKCb and CARMA1 are coordinately recruited to lipid
rafts upon BCR triggering and that CARMA1 binds both
PKCb isoforms via its linker region led these authors to
ask whether PKCb acts as an upstream kinase regulat-
ing CARMA1 function in B cells. In vitro phosphoryla-
tion studies identified three individual Ser residues
within the CARMA1 linker region as the targets of PKC-
mediated phosphorylation. Mutation of two of these
sites, Ser564 of murine CARMA1 (identical to Ser552
of human CARMA1) and Ser657 (corresponding to hu-
man Ser645) led to complete and partial reduction of
CARMA1-inducible NF-kB activity, respectively.
What are the molecular and functional consequences
of the PKC-dependent phosphorylation of the CARMA1
linker region? The study of Matsumoto, Wang, and col-
leagues shows that translocation into lipid rafts and im-
mune synapse enrichment of the Ser552 and Ser555
point mutants are not impaired, but recruitment of the
downstream signaling components BCL10 and IKKg/
NEMO is affected in CARMA1-deficient cells reconsti-
tuted with these mutants. Based on these findings, the
authors suggest that phosphorylation of the CARMA1
linker induces a conformational change that leads to
its dissociation from an inhibitor and/or exposes its
CARD motif for BCL10 recruitment.
The study of Sommer et al. provides elegant experi-
mental proof for the latter model by showing that
PKCq-dependent phosphorylation of a CARMA1 linker
construct reduced its capacity to bind to the CARD,
an effect that was not observed by a corresponding
linker construct mutated at Ser564 and Ser657. More-
over, CARMA1 constructs deleted in all or part of the
critical linker region behaved like constitutively active
mutants with respect to their membrane localization,
lipid raft enrichment, and capacity to recruit BCL10
and IKK and to induce NF-kB activation.
Collectively, the results of the two studies suggest
that CARMA1 resides in B and T cells in an inactive con-
formation in which the linker region binds to and blocks
the accessibility of the CARD motif. Antigen receptor-
triggered PKC-dependent linker phosphorylation is re-
quired to release this inhibition, thereby allowing for
BCL10 recruitment and signal propagation to the IKK
complex. In perfect agreement with this model, Shino-
hara and colleagues just reported a PKCb-dependent
phosphorylation of CARMA1. This phosphorylation cor-
related with CARMA1 binding to BCL10 and MALT1 and
also with recruitment of TGFb-activated kinase-1 (TAK1)
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552Figure 1. Schematic Representation of the PKC- and CARMA1-Dependent Signaling Pathway that Links Antigen Receptor Engagement to
NF-kB Activation
(A) Antigen receptor engagement leads to NF-kB activation via the activation of PKCb/PKCq, phosphorylation of CARMA1, and signal transmis-
sion via BCL10 and MALT1 to the NF-kB-regulating IKK complex.
(B) CARMA1 contains a CARD and a coiled coil motif that are separated from the MAGUK-typical PDZ, SH3, and GUK domains by a linker region.
This linker is proposed to contain a hinge region and a CARD binding domain (Sommer et al., 2005) and is the target of PKCb- or PKCq-dependent
phosphorylation (P) (Matsumoto et al., 2005; Sommer et al., 2005). The table summarizes the individual linker Ser residues identified by Matsu-
moto, Wang, et al. and Sommer et al. in human and murine CARMA1, respectively, and their confirmed (+) or excluded (2) involvement in the
indicated issues addressed by the two studies (ND, not determined).and subsequent TAK1-dependent IKK activation (Shi-
nohara et al., 2005).
Several interesting perspectives for future work
arise from these findings. The studies of Xin Lin’s
and David Rawling’s laboratories provide strong support
for PKCb/q-dependent phosphorylation of hSer552/
mSer564. However, the role of the functionally defective
mutant hSer555/mSer567 is less clear. It is likely that this
residue is not a target of phosphorylation, but instead
plays a structural role, such as facilitating the conforma-
tional change predicted to occur in the linker upon phos-
phorylation (Matsumoto et al., 2005; Sommer et al.,
2005).
Another open question that remains is the nature of
the kinase targeting hSer565/mSer577. This residue is
phosphorylated in PMA/CD28-stimulated Jurkat cells
(Matsumoto et al., 2005), but not by PKCq in vitro (Som-
mer et al., 2005), and does not match the consensus se-
quence for a PKC-dependent phosphorylation site.
However, the corresponding CARMA1 point mutant is
impaired in its capacity to activate NF-kB (Matsumoto
et al., 2005; Sommer et al., 2005). It seems thus likely
that CARMA1 is phosphorylated on this site by (an)other
kinase(s) activated upon antigen receptor triggering.
This is interesting in view of a recent study showing that
PI3K-dependent kinase-1 (PDK1) acts upstream of
CARMA1 in the NF-kB pathway (Lee et al., 2005).
PDK1 associates with both PKCq and CARMA1 and
controls their lipid raft recruitment in CD3/CD28-stimu-
lated Jurkat T cells (Lee et al., 2005). Therefore, the pos-
sibility of a direct PDK1-dependent phosphorylation of
CARMA1 should be considered.
In addition to the effects on the NF-kB pathway dis-
cussed here, it will be highly interesting to address the
role of CARMA1 phosphorylation in the activation ofthe JNK and p38 MAPK pathways, but also in the
CD40- and TLR4-dependent signaling events that have
been reported to be impaired in CARMA1-deficient or
mutant cells (Thome, 2004).
Based on the described CARMA1 linker mutants, the
generation of knockin mice expressing these mutants
and the generation of phosphorylation site-specific
antibodies should be useful in future studies exploring
the biological functions of CARMA1. Finally, as our un-
derstanding of the individual kinases and their target
sites increases, the specific pharmacological inhibition
of the phosphorylation of individual CARMA1 linker res-
idues may become a successful way to control diseases
caused by altered immune function.
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Poxviruses Aren’t StuPYD
Pathogens utilize many strategies to dampen the host
inflammatory response. In this issue of Immunity, a re-
port by Johnston and colleagues reveals a poxvirus
strategy that inhibits the inflammasome, arresting se-
cretion of interleukin-1-related cytokines, thus silenc-
ing key alarms that mobilize host defenses.
The host-pathogen relationship is complex, and in most
cases a balance exists between host control and path-
ogen escape from immune defenses. The poxviruses in
particular have evolved numerous strategies to inhibit
or dampen the host immune response to infection (Seet
et al., 2003). In their work, Johnston and colleagues de-
scribe the M13L protein that is encoded by a rabbit pox-
virus (myxoma virus) and that blocks the production of
interleukin (IL)-1 family cytokines from infected cells
(Johnston et al., 2005). M13L contains a pyrin domain
(PYD), a member of the ‘‘death-fold’’ family that is com-
posed of six tightly packed a helices to generate a
Greek key fold, which can interact specifically with a cel-
lular PYD-containing protein called ASC-1 (apoptosis-
associated speck-like protein containing a caspase re-
cruitment domain) (Masumoto et al., 1999). ASC-1 is a
component of the ‘‘inflammasome,’’ a multiprotein com-
plex located in the cytosol that is responsible for acti-
vation of proinflammatory caspases (cysteine-based
aspartic acid-specific proteinases, caspase-1, -4, and -5
in humans). Active caspase-1 and/or caspase-5 pro-
teolytically process proIL-1b (and IL-18) to its active
form in the cytosol (Martinon and Tschopp, 2004). John-
ston et al. show that M13L-PYD inhibits the activation of
procaspase-1 and subsequent secretion of IL-1b and
IL-18 from myxoma-infected cells (Johnston et al.,
2005). The authors establish the importance of M13L-
PYD in the course of myxoma infection by using a mu-
tant virus deleted in the PYD domain of the M13L gene.
This mutant virus caused a limited infection that failed to
spread from the initial site of inoculation, demonstrating
that the M13L protein contributes to the virulence in this
host and underscoring the importance of the IL-1 family
in mounting effective defenses.
Tight regulation of the production of proinflammatory
cytokines is required to maintain the homeostasis of
host tissues. Insufficient control of IL-1 production
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inflamed tissues and organ damage. There are several
types of these autoinflammatory diseases in humans
(e.g., Muckle-Wells syndrome, familial cold urticaria,
and familial Mediterranean fever) where mutations in
key components of the inflammasome are thought to
contribute to disease (Martinon and Tschopp, 2004).
NALP3 promotes inflammasome assembly and is fre-
quently mutated in its NACHT/NOD domain, leading
to increased ‘‘signal-independent’’ activation of IL-1b
processing (Agostini et al., 2004). Most components of
the inflammasome (e.g., NALP, ASC-1, caspases, and
others) encode multiple protein-interaction domains
(e.g., PYD, CARD, and NOD/NACT) that promote homo-
typic interactions between molecules that contain simi-
lar domains, forming the scaffold of the inflammasome.
For instance, ASC-1 contains both a PYD and a CARD
and can function as a molecular bridge through its inter-
action with the PYD of various NALP and the CARD of
caspase-1 (see Figure 1 inset).
Unlike most inflammasome components, M13L-PYD
contains a single PYD domain at its N terminus and
can interact with ASC-1 through a PYD-PYD association
(Johnston et al., 2005). This association of M13L-PYD
may disrupt the ability of ASC-1 to form the bridge
between caspases and various NALP, resulting in the
inhibition of caspase-1 activation. A cellular PYD-only-
protein (POP1) that interacts with ASC-1 has been de-
scribed, but POP1 does not appear to arrest IL-1b pro-
duction (Stehlik et al., 2003), suggesting that M13L-PYD
utilizes a distinct mechanism of action from POP1. One
possible model is shown in Figure 1, wherein M13L-PYD
disrupts the formation of a NALP3-containing inflam-
masome through its interaction with ASC-1. However,
several molecularly distinct inflammasomes exist, each
composed of a particular combination of death-fold-
containing adaptor proteins (Martinon and Tschopp,
2004). The exact nature of the inflammasome that is in-
duced by myxoma infection, and consequently inhibited
by M13L-PYD, is currently unknown, but its future iden-
tification will certainly add mechanistic insight to how
M13L-PYD functions to inhibit inflammation.
How does myxoma virus infection activate the inflam-
masome? Although numerous studies have dissected
the molecular aspects of protein-protein interactions
that regulate inflammasome assembly, to date the num-
ber of known physiological ligands/stimuli that catalyze
the assembly are limited. Bacterial muropeptide compo-
nents of peptidoglycans bind directly to the leucine-rich
